C. Christopher Hook

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, Mythri Mudireddy, Maura Nicolosi et al. · Mayo Clinic Proceedings · 2019 · 151 citations

Hematological Malignancy, Medicine, Outcomes Data +10

Thalidomide treatment in myelofibrosis with myeloid metaplasia

Michelle A. Elliott, Ruben A. Mesa, Chin‐Yang Li et al. · British Journal of Haematology · 2002 · 125 citations · Full text

Antifibrotic Therapy, Immunology, Pathology +18

Clinical Heterogeneity of the VEXAS Syndrome

Matthew J. Koster, Taxiarchis Kourelis, Kaaren K. Reichard et al. · Mayo Clinic Proceedings · 2021 · 103 citations

Down Syndrome, Rheumatology, Venous Disease +6

Low‐dose, single‐fraction, whole‐lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia

David P. Steensma, C. Christopher Hook, Scott L. Stafford et al. · British Journal of Haematology · 2002 · 94 citations · Full text

Heart Failure, Pulmonary Hypertension, Grim Prognosis +17

A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia

Ruben A. Mesa, Ayalew Tefferi, Michelle A. Elliott et al. · British Journal of Haematology · 2001 · 42 citations